Hepatocellular Carcinoma

Neoadjuvant immunotherapy Libtayo administered before surgical resection led to tumor necrosis in about one-third of patients with hepatocellular carcinoma, according to data published in The Lancet Gastroenterology and Hepatology.

Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced, unresectable hepatocellular carcinoma, according to research scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.

The FDA granted fast track designation to LioCyx-M004, a T-cell receptor T-cell therapy for treatment of adults with hepatitis B virus-related hepatocellular carcinoma.

New data suggest that failure to achieve sustained virologic response after treatment with direct-acting antivirals for hepatitis C was a strong predictor for development of hepatocellular carcinoma.

Patients with hepatitis C virus have always carried an increased risk for developing hepatocellular carcinoma. Although antiviral treatment for HCV reduces that risk, it is not eliminated.

In the era of direct-acting antivirals, rates of hepatocellular carcinoma are rising in patients without cirrhosis, particularly Black patients, according to a presentation at The Liver Meeting Digital Experience.

Healio Gastroenterology and Hepatology presents the following report on highlights from The Liver Meeting Digital Experience.

The FDA granted orphan drug designation to rivoceranib for the treatment of hepatocellular carcinoma.

This month’s cover story highlights the growing burden of hepatocellular carcinoma, the most common type of primary liver cancer, in the United States. Despite being a cancer that does not typically receive much attention, HCC is projected to become the third leading cause of cancer-related death in the United States by 2040 if current trends continue. Its increasing mortality is related to a growing number of cases in the setting of non-alcoholic fatty liver disease, the liver manifestation of the metabolic syndrome, and a high proportion of HCC cases being detected at a late stage. While patients detected at an early stage are amenable to curative therapies such as liver transplantation and have a median survival exceeding 5 years, those diagnosed at a late stage traditionally have had limited therapeutic options and a median survival of only 1 year.

Liver cancer — the fastest-growing cause of cancer death in the U.S. — has been notoriously difficult to treat.